Correcting the ASCO position on phase I clinical trials in cancer
Correcting the ASCO position on phase I clinical trials in cancer
Related Articles
Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA
Nature Reviews Clinical Oncology – Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA
Second-line tarlatamab improves OS in SCLC
Nature Reviews Clinical Oncology – Second-line tarlatamab improves OS in SCLC
Robot-assisted laparoscopic surgery confers improved oncological outcomes
Nature Reviews Clinical Oncology – Robot-assisted laparoscopic surgery confers improved oncological outcomes
Adding durvalumab to perioperative FLOT improves gastric cancer outcomes
Nature Reviews Clinical Oncology – Adding durvalumab to perioperative FLOT improves gastric cancer outcomes
The next generation of immunotherapies for lung cancers
Nature Reviews Clinical Oncology – Immune-checkpoint inhibitors (ICIs) have improved lung cancer outcomes, although resistance to these agents presents a substantial challenge. This Review…
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests
Nature Reviews Clinical Oncology – Liquid biopsy-based tests have demonstrated potential as a minimally invasive and broadly applicable approach to simultaneously screen individuals for multiple…
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC
Nature Reviews Clinical Oncology – Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC
Nature Reviews Clinical Oncology – Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC
T-DXd effective as second-line therapy in G/GEJ cancers
Nature Reviews Clinical Oncology – T-DXd effective as second-line therapy in G/GEJ cancers
A new first-line standard-of-care for BRAFV600E-mutated mCRC
Nature Reviews Clinical Oncology – A new first-line standard-of-care for BRAFV600E-mutated mCRC